Ovid Therapeutics Inc. Common Stock (OVID) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with OVID
Recent news

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
OVID

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
OVID

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
OVID

Here's Why Ovid Therapeutics Stock Popped Higher Today
Here's Why Ovid Therapeutics Stock Popped Higher Today
OVID
Technical indicators
- RSI 14
- 32.85
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.02
- SMA 50
- $2.64
- Price below SMA 50
- EMA 50
- $2.55
- Price below EMA 50
- SMA 200
- $2.32
- Price below SMA 200
- EMA 200
- $2.27
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
OVID

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
OVID

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
OVID

Here's Why Ovid Therapeutics Stock Popped Higher Today
Here's Why Ovid Therapeutics Stock Popped Higher Today
OVID

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
OVID

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
OVID

The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
OVID

3 Biotech Stocks Under $10 to Add to Your Buy List
3 Biotech Stocks Under $10 to Add to Your Buy List
OVID

Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
OVID
About Ovid Therapeutics Inc. Common Stock
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Margaret Alexander | CEO, President & Director | 1981 |
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder & Executive Chairman | 1953 |
| Mr. Charles Ross Carter M.B.A., M.S. | CFO, Principal Financial Officer, Principal Accounting Officer & Secretary | 1967 |
| Mr. Jeffrey A. Rona | Advisor | 1968 |
| Dr. Zhong Zhong Ph.D. | Chief Scientific Officer | — |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development | 1975 |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research | — |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer | — |
| Ms. Victoria Fort | Chief Strategy Officer | — |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer | 1966 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 32.85
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.02
- SMA 50
- $2.64
- Price below SMA 50
- EMA 50
- $2.55
- Price below EMA 50
- SMA 200
- $2.32
- Price below SMA 200
- EMA 200
- $2.27
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $5.00
- Average
- $7.00
- High
- $9.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +32.1 | +28.2 | -2.2 | +5.1 | -17.2 | +14.6 | -9.8 | -9.9 |



